{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:09:49Z","timestamp":1793916589321,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Spectral Medical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Given the success of recent platform trials for COVID-19, Bayesian statistical methods have become an option for complex, heterogenous syndromes like sepsis. However, study design will require careful consideration of how statistical power varies using Bayesian methods across different choices for how historical data are incorporated through a prior distribution and how the analysis is ultimately conducted. Our objective with the current analysis is to assess how different uses of historical data through a prior distribution, and type of analysis influence results of a proposed trial that will be analyzed using Bayesian statistical methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a simulation study incorporating historical data from a published multicenter, randomized clinical trial in the US and Canada of polymyxin B hemadsorption for treatment of endotoxemic septic shock. Historical data come from a 179-patient subgroup of the previous trial of adult critically ill patients with septic shock, multiple organ failure and an endotoxin activity of 0.60\u20130.89. The trial intervention consisted of two polymyxin B hemoadsorption treatments (2\u00a0h each) completed within 24\u00a0h of enrollment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In our simulations for a new trial of 150 patients, a range of hypothetical results were observed. Across a range of baseline risks and treatment effects and four ways of including historical data, we demonstrate an increase in power with the use of clinically defensible incorporation of historical data. In one possible trial result, for example, with an observed reduction in risk of mortality from 44 to 37%, the probability of benefit is 96% with a fixed weight of 75% on prior data and 90% with a commensurate (adaptive-weighting) prior; the same data give an 80% probability of benefit if historical data are ignored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using Bayesian methods and a biologically justifiable use of historical data in a prior distribution yields a study design with higher power than a conventional design that ignores relevant historical data. Bayesian methods may be a viable option for trials in critical care medicine where beneficial treatments have been elusive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13054-023-04717-x","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:02:25Z","timestamp":1699459345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bayesian methods: a potential path forward for sepsis trials"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-6399","authenticated-orcid":false,"given":"George","family":"Tomlinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Khafaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4014-969X","authenticated-orcid":false,"given":"Steven A.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-9825","authenticated-orcid":false,"given":"Faith N. F.","family":"Factora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Galphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-194X","authenticated-orcid":false,"given":"Kyle J.","family":"Gunnerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa","family":"Kohli-Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil K.","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-7637","authenticated-orcid":false,"given":"Ronald G.","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Sebastien","family":"Rachoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Rains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tidswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-2653","authenticated-orcid":false,"given":"John A.","family":"Kellum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"issue":"8","key":"4717_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"20","key":"4717_CR2","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, Berry S, Clermont G, Cooper G, Gomez H, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003\u201317.","journal-title":"JAMA"},{"issue":"2","key":"4717_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-2600(20)30471-9","volume":"9","author":"CJ Yarnell","year":"2021","unstructured":"Yarnell CJ, Abrams D, Baldwin MR, Brodie D, Fan E, Ferguson ND, Hua M, Madahar P, McAuley DF, Munshi L, et al. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making? Lancet Respir Med. 2021;9(2):207\u201316.","journal-title":"Lancet Respir Med"},{"issue":"1 Suppl","key":"4717_CR4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/CCM.0b013e318192078b","volume":"37","author":"D Annane","year":"2009","unstructured":"Annane D. Improving clinical trials in the critically ill: unique challenge\u2013sepsis. Crit Care Med. 2009;37(1 Suppl):S117-128.","journal-title":"Crit Care Med"},{"key":"4717_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2307\/2347264","volume":"35","author":"A Racine","year":"1986","unstructured":"Racine A, Grieve AP, Fl\u00fchler H, Smith AF. Bayesian methods in practice: experiences in the pharmaceutical industry. Appl Stat. 1986;35:93\u2013150.","journal-title":"Appl Stat"},{"key":"4717_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2307\/2983527","volume":"157","author":"DJ Spiegelhalter","year":"2008","unstructured":"Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc Ser Stat Soc. 2008;157:357.","journal-title":"J R Stat Soc Ser Stat Soc"},{"issue":"11","key":"4717_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jacc.2004.01.035","volume":"43","author":"GA Diamond","year":"2004","unstructured":"Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol. 2004;43(11):1929\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4717_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","volume":"5","author":"DA Berry","year":"2006","unstructured":"Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27\u201336.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4717_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10543400701668266","volume":"18","author":"BP Hobbs","year":"2008","unstructured":"Hobbs BP, Carlin BP. Practical Bayesian design and analysis for drug and device clinical trials. J Biopharm Stat. 2008;18(1):54\u201380.","journal-title":"J Biopharm Stat"},{"key":"4717_CR10","doi-asserted-by":"crossref","unstructured":"Moye LA. Bayesians in clinical trials: asleep at the switch. Stat Med. 2008;27(4):469\u201382 (discussion 483-469).","DOI":"10.1002\/sim.2928"},{"issue":"25","key":"4717_CR11","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/sim.5404","volume":"31","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012;31(25):2955\u201372.","journal-title":"Stat Med"},{"issue":"10","key":"4717_CR12","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1097\/CCM.0000000000000576","volume":"42","author":"AC Kalil","year":"2014","unstructured":"Kalil AC, Sun J. Bayesian methodology for the design and interpretation of clinical trials in critical care medicine: a primer for clinicians. Crit Care Med. 2014;42(10):2267\u201377.","journal-title":"Crit Care Med"},{"issue":"21","key":"4717_CR13","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2018.14276","volume":"320","author":"EC Goligher","year":"2018","unstructured":"Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Juni P, Brodie D, Slutsky AS, Combes A. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA. 2018;320(21):2251\u20139.","journal-title":"JAMA"},{"issue":"14","key":"4717_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"issue":"12","key":"4717_CR15","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205\u201312.","journal-title":"Intensive Care Med"},{"issue":"10","key":"4717_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1097\/00003246-199510000-00007","volume":"23","author":"JC Marshall","year":"1995","unstructured":"Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638\u201352.","journal-title":"Crit Care Med"},{"issue":"1","key":"4717_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13613-021-00928-z","volume":"11","author":"K Fujimori","year":"2021","unstructured":"Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021;11(1):141.","journal-title":"Ann Intensive Care"},{"issue":"3","key":"4717_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000475982","volume":"44","author":"AD Romaschin","year":"2017","unstructured":"Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017;44(3):193\u20137.","journal-title":"Blood Purif"},{"issue":"32","key":"4717_CR19","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, Gagnier J, Borenstein M, van der Heijden G, Dahabreh IJ, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192(32):E901\u20136.","journal-title":"CMAJ"},{"issue":"4\u20135","key":"4717_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1159\/000513213","volume":"50","author":"K Fujimori","year":"2021","unstructured":"Fujimori K, Tarasawa K, Fushimi K. Effects of polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan. Blood Purif. 2021;50(4\u20135):560\u20135.","journal-title":"Blood Purif"},{"issue":"23","key":"4717_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445\u201352.","journal-title":"JAMA"},{"issue":"9","key":"4717_CR22","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1097\/CCM.0b013e31828cf412","volume":"41","author":"F Zhou","year":"2013","unstructured":"Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2209\u201320.","journal-title":"Crit Care Med"},{"key":"4717_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcrc.2020.09.007","volume":"63","author":"X Li","year":"2021","unstructured":"Li X, Liu C, Mao Z, Qi S, Song R, Zhou F. Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock: a systematic review and meta-analysis. J Crit Care. 2021;63:187\u201395.","journal-title":"J Crit Care"},{"issue":"3","key":"4717_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","volume":"29","author":"SJ Pocock","year":"1976","unstructured":"Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29(3):175\u201388.","journal-title":"J Chronic Dis"},{"issue":"2","key":"4717_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1198\/000313006X109269","volume":"60","author":"F De Santis","year":"2006","unstructured":"De Santis F. Power priors and their use in clinical trials. Am Stat. 2006;60(2):122\u20139.","journal-title":"Am Stat"},{"issue":"24","key":"4717_CR26","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1002\/sim.9124","volume":"40","author":"LM Carvalho","year":"2021","unstructured":"Carvalho LM, Ibrahim JG. On the normalized power prior. Stat Med. 2021;40(24):5251\u201375.","journal-title":"Stat Med"},{"issue":"3","key":"4717_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1541-0420.2011.01564.x","volume":"67","author":"BP Hobbs","year":"2011","unstructured":"Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics. 2011;67(3):1047\u201356.","journal-title":"Biometrics"},{"issue":"4","key":"4717_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/00031305.2021.1901782","volume":"75","author":"K Kunzmann","year":"2021","unstructured":"Kunzmann K, Grayling MJ, Lee KM, Robertson DS, Rufibach K, Wason JMS. A review of bayesian perspectives on sample size derivation for confirmatory trials. Am Stat. 2021;75(4):424\u201332.","journal-title":"Am Stat"},{"issue":"2","key":"4717_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/bimj.201800395","volume":"62","author":"A Kopp-Schneider","year":"2020","unstructured":"Kopp-Schneider A, Calderazzo S, Wiesenfarth M. Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control. Biom J. 2020;62(2):361\u201374.","journal-title":"Biom J"},{"issue":"11","key":"4717_CR30","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143.","journal-title":"Crit Care Med"},{"issue":"3","key":"4717_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/ALN.0000000000002820","volume":"131","author":"A Putzu","year":"2019","unstructured":"Putzu A, Schorer R, Lopez-Delgado JC, Cassina T, Landoni G. Blood purification and mortality in sepsis and septic shock: a systematic review and meta-analysis of randomized trials. Anesthesiology. 2019;131(3):580\u201393.","journal-title":"Anesthesiology"},{"issue":"8","key":"4717_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"7","key":"4717_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","volume":"17","author":"DC Angus","year":"2020","unstructured":"Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M, Broglio K, Brunkhorst F, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study rationale and design. Ann Am Thorac Soc. 2020;17(7):879\u201391.","journal-title":"Ann Am Thorac Soc"},{"key":"4717_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12561-021-09318-2","volume":"14","author":"HC Quan","year":"2022","unstructured":"Quan HC, Chen X, Luo X. Assessments of conditional and unconditional type I error probabilities for bayesian hypothesis testing with historical data borrowing. Stat Biosci. 2022;14:139\u201357.","journal-title":"Stat Biosci"},{"key":"4717_CR35","unstructured":"US Food and Drug Aministration. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials [https:\/\/www.fda.gov\/media\/71512\/download] Accessed October 9, 2023."}],"updated-by":[{"DOI":"10.1186\/s13054-023-04791-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000}}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04717-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T19:05:31Z","timestamp":1704308731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04717-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13054-023-04791-1","asserted-by":"object"}]},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13054-023-04791-1","URL":"https:\/\/doi.org\/10.1186\/s13054-023-04791-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For the parent study, Euphrates, all procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975. Prior to randomization, informed consent was obtained from all subjects or their surrogates based on meeting all of the eligibility criteria. The first institutional IRB approval was obtained on 05\/18\/2010 from Cooper University Hospital IRB (#09-144). The study is registered with clinicaltrials.gov as [NCT01046669].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GT is a paid consultant to Spectral Medical. DMF, and JAK are employees of Spectral Medical. PMW is a member of the Board of Directors of Spectral Medical. AA-K, SAC, FNF, CG, KG, SK, RK-S, PM, NKM, RGP, J-SR, RR, MS and MT are\/were investigators in the Tigris and\/or EUPHRATES trials and their institutions received funding to conduct the studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}